Canada· CA-DIN-02510839
VYEPTI
A eptinezumab product containing eptinezumab, registered in Canada by LUNDBECK CANADA INC. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- EPTINEZUMAB
- Manufacturer
- LUNDBECK CANADA INC
- Country
- Canada (CA)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- BelgiumVyepti 100 mgH. Lundbeck
- SwitzerlandVyepti 100 mg/1 ml, Konzentrat zur Herstellung einer InfusionslösungLundbeck (Schweiz) AG
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
- NorwayVyeptiH. Lundbeck A/S
- PolandVyeptiH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d44e5747-abf8-4ab8-8687-5f75283bda0b GET /v1/drugs/d44e5747-abf8-4ab8-8687-5f75283bda0b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02510839",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "N02CD05",
"schedule": [
"Prescription",
"Schedule D"
],
"drug_code": "100002",
"strengths": [
"100 MG"
],
"ahfs_class": null,
"substances": [
"EPTINEZUMAB"
],
"product_categorization": null
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.